AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30294825 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice (n = 47)
Number of subjects: 105
Study 27900446 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus bendamustine (G-B)
Number of subjects: 396
Study 27900446 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine alone (B)
Number of subjects: 396
Study 26176927 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 100
Study 26176927 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 100
Study 23271192 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 2 mg
Number of subjects: 15
Study 23271192 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 5 mg
Number of subjects: 15
Study 23271192 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg
Number of subjects: 15
Study 23271192 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg
Number of subjects: 15
Study 23271192 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (all doses)
Number of subjects: 15
Study 20957705 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat with cognitive‐behavioral therapy, guided‐self‐help (CBTgsh)
Number of subjects: 50
Study 19609438 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) as regular therapy
Number of subjects: 159
Study 16750253 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 100
Study 16750253 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 100
Study 15133343 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (three times every 3 hours)
Number of subjects: 14
Study 15133343 — intervention group
Group type: COMPARATOR
Intervention: Non-treated healthy volunteers (control)
Number of subjects: 14
Study 11358560 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole nitrate 0.25%
Number of subjects: 202
Study 11358560 — intervention group
Group type: COMPARATOR
Intervention: Ointment base alone
Number of subjects: 202
Study 9519354 — intervention group
Group type: EXPERIMENTAL
Intervention: buserelin plus cyproterone acetate
Number of subjects: 695
Study 9519354 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide
Number of subjects: 695
Study 9519354 — intervention group
Group type: EXPERIMENTAL
Intervention: maximal androgen blockade (MAB)
Number of subjects: 695
Study 8024677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 20 mg
Number of subjects: 27
Study 8024677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 10 mg
Number of subjects: 27
Study 8024677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (various doses)
Number of subjects: 27
Study 2803886 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscopy and intubation
Number of subjects: 23
Study 2803886 — intervention group
Group type: COMPARATOR
Intervention: Blind nasal intubation
Number of subjects: 23
Study 136815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 28
Study 136815 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic-acid
Number of subjects: 28
Study 30293693 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 43
Study 30293693 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacotherapy alone
Number of subjects: 43
Study 27175903 — intervention group
Group type: EXPERIMENTAL
Intervention: CHANGE! intervention
Number of subjects: 60
Study 26599219 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 43
Study 26599219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 25086490 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty (RSA)
Number of subjects: 62
Study 25086490 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 62
Study 22371898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lersivirine (LRV) 2,400 mg
Number of subjects: 48
Study 22371898 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 48
Study 22371898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20188228 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based exercise program
Number of subjects: 204
Study 20188228 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group (control)
Number of subjects: 204
Study 17355729 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin photodynamic therapy combined with anti-angiogenic agents (ranibizumab or pegaptanib)
Number of subjects: 0
Study 17355729 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-angiogenic agents (ranibizumab or pegaptanib)
Number of subjects: 0
Study 17355729 — intervention group
Group type: COMPARATOR
Intervention: Verteporfin photodynamic therapy
Number of subjects: 0
Study 17355729 — intervention group
Group type: COMPARATOR
Intervention: Anti-angiogenic agents
Number of subjects: 0
Study 16222916 — intervention group
Group type: EXPERIMENTAL
Intervention: Water fortified with 10 mg elemental iron and 100 mg ascorbic acid per liter
Number of subjects: 150
Study 16222916 — intervention group
Group type: COMPARATOR
Intervention: Water containing only 100 mg ascorbic acid per liter
Number of subjects: 150
Study 12208222 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1‐0.4 microg x kg(‐1) x min(‐1))
Number of subjects: 504
Study 12208222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study 10521382 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg)
Number of subjects: 30
Study 10521382 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg)
Number of subjects: 30
Study 10521382 — intervention group
Group type: COMPARATOR
Intervention: LPS (4 ng/kg IV)
Number of subjects: 30
Study 7484997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine (1.5 g/day) for 12 weeks after surgery
Number of subjects: 21
Study 7484997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7484997 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of lesions at perioperative endoscopy (POE)
Number of subjects: 21
Study 7484997 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of lesions at perioperative endoscopy (POE)
Number of subjects: 21
Study 2049250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein meal (10.5 g of protein)
Number of subjects: 8
Study 2049250 — intervention group
Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 8
Study 2049250 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal (30.5 g of protein)
Number of subjects: 8
Study 7451775 — intervention group
Group type: EXPERIMENTAL
Intervention: Venom skin testing
Number of subjects: 128
Study 7451775 — intervention group
Group type: COMPARATOR
Intervention: Whole body extract (WBE) skin testing
Number of subjects: 128
Study 7451775 — intervention group
Group type: EXPERIMENTAL
Intervention: Venom skin testing at concentrations of 1 microgram/ml or less
Number of subjects: 128
Study 7451775 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 128
Study 6299612 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 6299612 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6
Study 6299612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6299612 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (Propranolol and Atenolol)
Number of subjects: 6
Study 31639058 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of mother on HIV exposed infant feeding practice
Number of subjects: 358
Study 31639058 — intervention group
Group type: EXPERIMENTAL
Intervention: Head of family being father
Number of subjects: 358
Study 31639058 — intervention group
Group type: EXPERIMENTAL
Intervention: Having family (relatives) support
Number of subjects: 358
Study 31639058 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on HIV exposed infant feeding practice
Number of subjects: 358
Study 29478874 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-Focused Cognitive Therapy (MFCT) sessions (5×120min in 1 week)
Number of subjects: 30
Study 29478874 — intervention group
Group type: COMPARATOR
Intervention: Control group (ongoing treatment-as-usual; TAU)
Number of subjects: 30
Study 25873297 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy manipulation (recalled personal experiences of empathising with others) in Japan
Number of subjects: 160
Study 25873297 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition in Japan
Number of subjects: 160
Study 25873297 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy manipulation in Australia
Number of subjects: 160
Study 25873297 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition in Australia
Number of subjects: 160
Study 24568566 — intervention group
Group type: EXPERIMENTAL
Intervention: Male who used a stimulant to study
Number of subjects: 695
Study 24568566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmedical use of prescription stimulants (NMUPS) as a study aid
Number of subjects: 695
Study 23075175 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral-blood stem cells
Number of subjects: 551
Study 23075175 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow
Number of subjects: 551
Study 20454993 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38
Number of subjects: 16
Study 20454993 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP
Number of subjects: 16
Study 20454993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17363405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl PCA
Number of subjects: 28
Study 17363405 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural block with bupivacaine plus fentanyl
Number of subjects: 28
Study 17363405 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 28
Study 15874889 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position ventilation
Number of subjects: 42
Study 15874889 — intervention group
Group type: COMPARATOR
Intervention: Supine position ventilation
Number of subjects: 42
Study 12592266 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone acetate + phosphate
Number of subjects: 105
Study 12592266 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate
Number of subjects: 105
Study 12592266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Number of subjects: 105
Study 12592266 — intervention group
Group type: COMPARATOR
Intervention: Control (after treatment)
Number of subjects: 105
Study 10937985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine
Number of subjects: 200
Study 10937985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 10226245 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 34
Study 10226245 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 34
Study 1755063 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic intervention for Ascaris lumbricoides infection
Number of subjects: 1206
Study 1755063 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment (control)
Number of subjects: 1206
Study 7041831 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg levamisole
Number of subjects: 281
Study 7041831 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg levamisole
Number of subjects: 281
Study 7041831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 7041831 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg levamisole (classical dosage schedule)
Number of subjects: 281
Study 31496244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Number of subjects: 100
Study 28321001 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB/CCB combination therapy (irbesartan 100 mg + amlodipine 5 mg)
Number of subjects: 411
Study 28321001 — intervention group
Group type: COMPARATOR
Intervention: ARB/diuretic combination (daily irbesartan 100 mg + trichlormethiazide 1 mg)
Number of subjects: 411
Study 26445302 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) administered orally for 48 hours before and 24 hours after coronary angiography
Number of subjects: 132
Study 26445302 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration (isotonic saline)
Number of subjects: 132
Study 23644107 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndrome differentiation-based treatment with traditional Chinese medicine (TCM)
Number of subjects: 81
Study 23644107 — intervention group
Group type: COMPARATOR
Intervention: Oral losartan therapy (50 mg/day)
Number of subjects: 81
Study 21538174 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow, deep breathing (6 breaths per min)
Number of subjects: 267
Study 21538174 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing (15 breaths per min)
Number of subjects: 267
Study 19428297 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of casopitant mesylate (150 mg)
Number of subjects: 810
Study 19428297 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day intravenous plus oral casopitant mesylate (90 mg intravenous on day 1 plus 50 mg oral on days 2 and 3)
Number of subjects: 810
Study 19428297 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 810
Study 17021784 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% trichloroacetic acid (TCA)
Number of subjects: 215
Study 17021784 — intervention group
Group type: COMPARATOR
Intervention: Ear drops containing antibiotic and corticosteroid (Control)
Number of subjects: 215
Study 15506300 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu group (XF)
Number of subjects: 123
Study 15506300 — intervention group
Group type: EXPERIMENTAL
Intervention: Jingzhi Xuefu Zhuyu group (JZ)
Number of subjects: 123
Study 15506300 — intervention group
Group type: EXPERIMENTAL
Intervention: Yaodui group (YD)
Number of subjects: 123
Study 15506300 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 123
Study 15506300 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 123
Study 11511607 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 11511607 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 0
Study 11511607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10524688 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly MTX
Number of subjects: 51
Study 10524688 — intervention group
Group type: EXPERIMENTAL
Intervention: Every-other-week (EOW) MTX
Number of subjects: 51
Study 10524688 — intervention group
Group type: COMPARATOR
Intervention: Control group (EOW MTX)
Number of subjects: 51
Study 7854226 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners recognizing mental health problems at least once per week
Number of subjects: 721
Study 7854226 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to referral
Number of subjects: 721
Study 7854226 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational priorities
Number of subjects: 721
Study 1937373 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure alcohol (PA, 99.8%)
Number of subjects: 84
Study 1937373 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% glucose in water (G/W)
Number of subjects: 84
Study 1937373 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% NaCl solution
Number of subjects: 84
Study 1937373 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (N/S)
Number of subjects: 84
Study 6129185 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + cyclic SRIF (100 micrograms/hr i.v.) for ten hours
Number of subjects: 5
Study 6129185 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (10 units as a bolus + infusion 1 U/hr)
Number of subjects: 5
Study 31665303 — intervention group
Group type: EXPERIMENTAL
Intervention: I-RED strategy
Number of subjects: 109
Study 31665303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109
Study 29790397 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar hemiarthroplasty
Number of subjects: 28
Study 29790397 — intervention group
Group type: COMPARATOR
Intervention: Bipolar hemiarthroplasty
Number of subjects: 28
Study 27091801 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care
Number of subjects: 48
Study 27091801 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study 24300751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg
Number of subjects: 15
Study 24300751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 22705428 — intervention group
Group type: EXPERIMENTAL
Intervention: Starvation
Number of subjects: 187
Study 22705428 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 187
Study 22705428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cachexia
Number of subjects: 187
Study 22705428 — intervention group
Group type: EXPERIMENTAL
Intervention: All three conditions (starvation, sarcopenia, cachexia)
Number of subjects: 187
Study 20437554 — intervention group
Group type: EXPERIMENTAL
Intervention: GKI infusion
Number of subjects: 40
Study 20437554 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 18768029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental hygiene activities including prophylaxis, sealants application, topical fluoride, fluoride mouthrinses, and tooth brushing instructional activity.
Number of subjects: 888
Study 15842138 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin
Number of subjects: 79
Study 15842138 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 79
Study 15842138 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medical treatment (Control)
Number of subjects: 79
Study 12578487 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg twice per day)
Number of subjects: 200
Study 12578487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12578487 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 200
Study 10475592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented milk formula
Number of subjects: 2
Study 10475592 — intervention group
Group type: COMPARATOR
Intervention: Standard milk formula
Number of subjects: 2
Study 8776276 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg 3 times daily)
Number of subjects: 19
Study 8776276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1377198 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching and reinforcement about babies' behavior from a child development specialist during NICU visits
Number of subjects: 41
Study 6431461 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 20
Study 6431461 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 20
Study 6431461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30151631 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved expectations about length of sick leave during rehabilitation
Number of subjects: 168
Study 30151631 — intervention group
Group type: COMPARATOR
Intervention: Reduced expectations about length of sick leave
Number of subjects: 168
Study 30151631 — intervention group
Group type: COMPARATOR
Intervention: Consistently negative expectations about length of sick leave
Number of subjects: 168
Study 29901548 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's milk feeding
Number of subjects: 300
Study 29901548 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding
Number of subjects: 300
Study 29901548 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation among infants receiving mother's milk
Number of subjects: 300
Study 29901548 — intervention group
Group type: EXPERIMENTAL
Intervention: Introducing solids between 4 and 6 months CA
Number of subjects: 300
Study 29901548 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 300
Study 29901548 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence to all recommendations
Number of subjects: 300
Study 26976287 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined incentive
Number of subjects: 304
Study 26976287 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual incentive
Number of subjects: 304
Study 26976287 — intervention group
Group type: EXPERIMENTAL
Intervention: Team incentive
Number of subjects: 304
Study 26976287 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 304
Study 21695523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich diet
Number of subjects: 11
Study 21695523 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich diet
Number of subjects: 11
Study 20216119 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 5
Study 18400939 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene treatment
Number of subjects: 7705
Study 18400939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 15797966 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/d, 16 wk)
Number of subjects: 31
Study 15797966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (16 wk)
Number of subjects: 31
Study 15797966 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 31
Study 15797966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11885802 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency Doubling Technology (FDT) C20‐1 screening algorithm
Number of subjects: 574
Study 11885802 — intervention group
Group type: COMPARATOR
Intervention: HFA 24-2 SITA-FAST
Number of subjects: 574
Study 10326324 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cyclosporin A
Number of subjects: 208